• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GI Dynamics axes medical chief Maggs | Personnel Moves

GI Dynamics axes medical chief Maggs | Personnel Moves

June 23, 2015 By Brad Perriello

MassDevice.com Personnel Moves

GI Dynamics (ASX:GID) said last week in a regulatory filing that it fired chief medical officer Dr. David Maggs “for cause.”

The Lexington, Mass.-based medical device company did not otherwise elaborate on the reason for Maggs’s departure, which was effective June 18, according to the filing.

Maggs joined GI Dynamics in April 2013 to oversee the clinical development of its EndoBarrier device, a gut liner designed to induce weight loss and help control diabetes in obese patients.

GID shares lost half their value earlier this year after the company revealed that the FDA halted enrollment in a U.S. clinical trial for EndoBarrier, after 4 patients developed bacterial infections known as hepatic abscesses. The company had already been struggling to overcome news late last year that European regulators had halted EndoBarrier sales there. Shipments resumed in December 2014 after the product’s labeling was modified to include certain prescribing restrictions, but GI Dynamics still laid off 10% of its workforce that month, including its longtime CFO.

CEO Stuart Randle stepped down in August 2014, succeeded by ex-ATS Medical chief Michael Dale.

In April of this year the company exercised a 1-for-10 reverse stock split to bolster its flagging stock price.

 AxoGen marketing chief Schiaparelli jumps ship for mystery CEO role
AxoGen Inc. (NSDQ:AXGN) said last week that its chief marketing officer, Jill Schiaparelli, resigned to take the CEO spot at an unnamed life sciences company. Schiaparelli, who joined AxoGen in 2012, is a director at Intelomed.
Read more

 Gamma Medica snags ex-LifeCell CEO Croxford
Gamma Medica said it replaced CEO Jim Calandra, who left to “pursue other opportunities,” with former LifeCell CEO Philip Croxford. The company also said it named Toshiba America Medical Systems vet Scott Headland as its new vice president of sales.
Read more

 EndoGastric Solutions expands team
EndoGastric Solutions said it added 3 new names to its executive roster: former St. Jude Medical (NYSE:STJ) senior vice president Mike Zagger as VP of sales & marketing; Given Imaging vet Philip Macdonald as VP of healthcare economics, policy & reimbursement; and Dr. Adrian Lobontiu, who re-joined as medical director after a year away from the company.
Read more

 Calhoun Vision taps LenSx co-founders Kurtz, Weinberg
Calhoun Vision said it named LenSx Lasers co-founders Dr. Ron Kurtz to be its new COO and Eric Weinberg as chief commercial officer. The company in March replaced former CEO Verne Sharma with Rick Heinick, a former Bausch & Lomb executive who helped lead the firm until its acquisition by Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) in 2013.
Read more

  • Histogenics names ex-MetaMark Genetics exec Lieber as CFO
  • New Cerus CMO Benjamin is Red Cross vet
  • Huntsman Cancer Inst. CEO Beckerle joins J&J board
  • Second Sight Medical names MannKind CFO Pfeffer to board
  • Health issues force InvaCare founder Mixon to retire

Filed Under: Business/Financial News Tagged With: AxoGen, Calhoun Vision, Cerus Corp., endogastricsolutions, Gamma Medica, GI Dynamics, Histogenics, Invacare, Johnson and Johnson, Personnel Moves, second-sight-medical

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy